变量 | |
年龄岁 | 48(32-69) |
男 | 49分之40(81.6%) |
移民身份 | 26/49(53.1%) |
占用 | |
Employed | 14/48(29.2%) |
Unemployed | 15/48(31.3%) |
Retired | 14/48(29.2%) |
Student | 5/48(10.4%) |
卡介苗接种 | 19/30(63.3%) |
COPD /哮喘 | 47分之8(17.0%) |
糖尿病 | 49分之8(16.3%) |
HIV感染 | 6/48(12.5%) |
肾功能衰竭 | 49分之5(10.2%) |
肝病 | 7/49(14.3%) |
滥用酒精# | 49分之10(20.4%) |
抽烟¶ | 49分之20(40.8%) |
吸毒 | 47分之4(8.5%) |
TB | |
Previous history of TB | 13/46(28.3%) |
Site | |
Pulmonary TB only | 49分之36(73.5%) |
Extrapulmonary TB only | 1/49(2.0%) |
Pulmonary TB/extrapulmonary TB (>1 site possible) | 49分之12(24.5%) |
Site of extrapulmonary TB | |
Bone | 2/13(15.4%) |
Lymphadenitis | 2/13(15.4%) |
Pleural | 2/13(15.4%) |
Central nervous system | 1/13(7.7%) |
Laryngeal | 1/13(7.7%) |
Gastrointestinal | 1/13(7.7%) |
Peritonitis+lymphadenitis+pleural+bone | 1/13(7.7%) |
Genitourinary+lymphadenitis | 1/13(7.7%) |
Central nervous system+lymphadenitis | 1/13(7.7%) |
Bone+joint+spondylodiscitis (T5-T11)+paravertebral abscesses | 1/13(7.7%) |
Radiological involvement | |
Unilateral cavitary lesions | 10/48(20.8%) |
Bilateral cavitary lesions | 13/48(27.1%) |
Bilateral infiltrates (no cavities) | 9/48(18.8%) |
Unilateral infiltrates | 16/48(33.3%) |
Microbiology | |
Sputum culture confirmation | 49分之22(44.9%)(8痰培养进行中) |
NAAT confirmation | 13/49(26.5%) |
Sputum smear positive | 9/49(18.4%) |
Not available | 49分之5(10.2%) |
Drug resistance | |
Resistant | 45分之8(17.8%)(4 MDR-TB) |
Sensitive | 37/45(82.2%) |
Treatment outcome | |
Cured | 6/49(12.2%) |
Completed | 1/49(2.0%) |
On treatment | 49分之37(75.5%) |
Died+ | 49分之5(10.2%) |
Lost to follow-up | 0 |
Failure | 0 |
新冠肺炎 | |
Symptoms | |
Asymptomatic | 5/48(10.4%) |
Symptomatic | 43/48(89.6%) |
Imaging | |
Typical (bilateral ground glass opacities) HRCT picture | 21/44(47.7%) |
Treatment outcome | |
Resolved | 49分之18(36.7%) |
Still on treatment | 25/49(51.0%) |
Died (at any date)+ | 6/49(12.3%) |
数据表示为对于人是可用的(%)或中值(四分位数间距)数据的患者数/总数。#:每周≥14饮料男性或每周≥7饮料的女性;¶:当前或戒烟者;+:根据治疗结果的队列分析的标准谁抗结核治疗过程中死亡的患者人数为五人,但死亡总数为六个,如一个病人后抗结核治疗后遗症而治愈结核病后死亡。BCG:卡介苗;NAAT:核酸扩增试验;MDR-TB:多药耐药结核;HRCT:高分辨率的计算机断层扫描。